A UK-based KOL discusses how currently available drugs have drastically changed the CML treatment landscape. This interview also covers physician perspectives on patient quality-of-life, unmet needs within the indication and a clinical trial overview of some of the most promising medicines in the development pipeline.

This interview was conducted on January 27, 2026.

If you are a Datamonitor Healthcare client, you may access the interview from our KOL Insight channel.

If you are a KOL Insight subscriber, you may also access the interview from our KOL Insight portal.

Biomedtracker’s KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900. 

For our disclosures, please read the Biomedtracker Research Standards.